TY - JOUR
T1 - Challenges in IBD Research: Novel Technologies
AU - Dhyani, Manish
AU - Joshi, Nitin
AU - Bemelman, Willem A.
AU - Gee, Michael S.
AU - Yajnik, Vijay
AU - D'Hoore, André
AU - Traverso, Giovanni
AU - Donowitz, Mark
AU - Mostoslavsky, Gustavo
AU - Lu, Timothy K.
AU - Lineberry, Neil
AU - Niessen, Heiko G.
AU - Peer, Dan
AU - Braun, Jonathan
AU - Delaney, Conor P.
AU - Dubinsky, Marla C.
AU - Guillory, Ashley N.
AU - Pereira, Maria
AU - Shtraizent, Nataly
AU - Honig, Gerard
AU - Polk, David Brent
AU - Hurtado-Lorenzo, Andrés
AU - Karp, Jeffrey M.
AU - Michelassi, Fabrizio
PY - 2019
Y1 - 2019
N2 - Novel technologies is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, precision medicine and pragmatic clinical research. The Challenges in IBD research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the novel technologies section is focused on prioritizing unmet clinical needs in IBD that will benefit from novel technologies applied to: 1) non-invasive detection and monitoring of active inflammation and assessment of treatment response; 2) mucosal targeted drug delivery systems; and 3) prevention of post-operative septic complications and treatment of fistulizing complications. Proposed approaches include development of multiparametric imaging modalities and biosensors, to enable non invasive or minimally invasive detection of pro-inflammatory signals to monitor disease activity and treatment responses. Additionally, technologies for local drug delivery to control unremitting disease and increase treatment efficacy while decreasing systemic exposure are also proposed. Finally, research on biopolymers and other sealant technologies to promote post-surgical healing; and devices to control anastomotic leakage and prevent post-surgical complications and recurrences are also needed.
AB - Novel technologies is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, precision medicine and pragmatic clinical research. The Challenges in IBD research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the novel technologies section is focused on prioritizing unmet clinical needs in IBD that will benefit from novel technologies applied to: 1) non-invasive detection and monitoring of active inflammation and assessment of treatment response; 2) mucosal targeted drug delivery systems; and 3) prevention of post-operative septic complications and treatment of fistulizing complications. Proposed approaches include development of multiparametric imaging modalities and biosensors, to enable non invasive or minimally invasive detection of pro-inflammatory signals to monitor disease activity and treatment responses. Additionally, technologies for local drug delivery to control unremitting disease and increase treatment efficacy while decreasing systemic exposure are also proposed. Finally, research on biopolymers and other sealant technologies to promote post-surgical healing; and devices to control anastomotic leakage and prevent post-surgical complications and recurrences are also needed.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85066832557&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31095703
U2 - https://doi.org/10.1093/ibd/izz077
DO - https://doi.org/10.1093/ibd/izz077
M3 - Article
C2 - 31095703
SN - 1078-0998
VL - 25
SP - S24-S30
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 2
ER -